###begin article-title 0
Connective Tissue Growth Factor Overexpression in Cardiomyocytes Promotes Cardiac Hypertrophy and Protection against Pressure Overload
###end article-title 0
###begin p 1
Conceived and designed the experiments: ANP AP CG RDIM CO. Performed the experiments: ANP MGP NA SKG BE EP CG CO. Analyzed the data: ANP MGP AP CG RDIM MB CO. Contributed reagents/materials/analysis tools: ANP RDIM. Wrote the paper: ANP MGP AP RDIM MB CO.
###end p 1
###begin p 2
###xml 1078 1080 1078 1080 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 222 237 <span type="species:ncbi:10090">transgenic mice</span>
###xml 242 246 <span type="species:ncbi:10116">rats</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
###xml 425 428 <span type="species:ncbi:10116">rat</span>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
###xml 776 780 <span type="species:ncbi:10090">mice</span>
###xml 1013 1017 <span type="species:ncbi:10090">mice</span>
Connective tissue growth factor (CTGF) is a secreted protein that is strongly induced in human and experimental heart failure. CTGF is said to be profibrotic; however, the precise function of CTGF is unclear. We generated transgenic mice and rats with cardiomyocyte-specific CTGF overexpression (CTGF-TG). To investigate CTGF as a fibrosis inducer, we performed morphological and gene expression analyses of CTGF-TG mice and rat hearts under basal conditions and after stimulation with angiotensin II (Ang II) or isoproterenol, respectively. Surprisingly, cardiac tissues of both models did not show increased fibrosis or enhanced gene expression of fibrotic markers. In contrast to controls, Ang II treated CTGF-TG mice displayed preserved cardiac function. However, CTGF-TG mice developed age-dependent cardiac dysfunction at the age of 7 months. CTGF related heart failure was associated with Akt and JNK activation, but not with the induction of natriuretic peptides. Furthermore, cardiomyocytes from CTGF-TG mice showed unaffected cellular contractility and an increased Ca2+ reuptake from sarcoplasmatic reticulum. In an ischemia/reperfusion model CTGF-TG hearts did not differ from controls.
###end p 2
###begin p 3
Our data suggest that CTGF itself does not induce cardiac fibrosis. Moreover, it is involved in hypertrophy induction and cellular remodeling depending on the cardiac stress stimulus. Our new transgenic animals are valuable models for reconsideration of CTGF's profibrotic function in the heart.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 56 59 56 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Kannel1">[1]</xref>
###xml 157 160 157 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Kannel1">[1]</xref>
###xml 162 165 162 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Levy1">[2]</xref>
###xml 251 254 251 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Chien1">[3]</xref>
###xml 580 583 574 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Grotendorst1">[4]</xref>
###xml 585 588 579 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Holmes1">[5]</xref>
###xml 590 593 584 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Khan1">[6]</xref>
###xml 725 728 716 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Blom1">[7]</xref>
###xml 730 733 721 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Grotendorst2">[8]</xref>
###xml 791 792 782 783 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 798 799 789 790 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 808 809 799 800 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</underline>
###xml 880 883 871 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Perbal1">[9]</xref>
###xml 885 889 876 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Bork1">[10]</xref>
###xml 1084 1087 1075 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Perbal1">[9]</xref>
###xml 1225 1229 1216 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Roestenberg1">[11]</xref>
###xml 1231 1235 1222 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Whitfield1">[12]</xref>
###xml 1237 1241 1228 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Gauldie1">[13]</xref>
###xml 1243 1247 1234 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Lang1">[14]</xref>
###xml 1249 1253 1240 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Yokoi1">[15]</xref>
###xml 1255 1259 1246 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Ohnishi1">[16]</xref>
###xml 1261 1265 1252 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Chen1">[17]</xref>
###xml 1267 1271 1258 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Matsui1">[18]</xref>
###xml 1273 1277 1264 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Koitabashi1">[19]</xref>
###xml 1378 1382 1369 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Matsui1">[18]</xref>
###xml 1384 1388 1375 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-He1">[20]</xref>
###xml 1481 1485 1472 1476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Hayata1">[21]</xref>
###xml 1558 1562 1549 1553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Koitabashi1">[19]</xref>
###xml 1564 1568 1555 1559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Koitabashi2">[22]</xref>
Heart failure is an increasing health problem worldwide [1]. The mortality rate averages 30% within the first year after diagnosis irrespective of treatment [1], [2]. Heart failure has numerous causes; however, the major pathomechanisms are universal [3]. The cardiac remodeling cascade involves initiation of adaptive cellular hypertrophy followed by left ventricular dilatation, decreased systolic function, cardiomyocyte loss, and development of fibrosis. The profibrotic and prohypertrophic changes in the heart are mainly driven by transforming growth factor-beta (TGF-beta) [4], [5], [6].Connective tissue growth factor (CTGF; also known as CCN2) is an extracellular matrix-secreted protein that is induced by TGF-beta [7], [8]. The protein belongs to the highly conserved CCN family (Cyr61, CTGF, and NOV) of growth factors that exerts a wide range of biological functions [9], [10]. CTGF regulates such diverse cellular processes as extra-cellular matrix (ECM) deposition, wound repair, angiogenesis, migration, and differentiation, as well as cell survival and proliferation [9]. However, the most prominent feature of CTGF is its overexpression in fibrosis of various organs including lung, kidney, skin, and heart [11], [12], [13], [14], [15], [16], [17], [18], [19]. Angiotensin II (Ang II), epinephrine, and mechanical stress induce CTGF in cultured cardiomyocytes [18], [20]. Other studies showed that CTGF also exhibited prohypertrophic properties on cardiomyocytes [21]. Furthermore, serum CTGF has been proposed as a heart failure biomarker [19], [22]. The diversity of findings regarding CTGF and its role in heart failure prompted us to investigate CTGF function in two different rodent models of CTGF overexpression in the heart.
###end p 5
###begin title 6
Results
###end title 6
###begin title 7
Expression and localization of CTGF in CTGF-TG animals
###end title 7
###begin p 8
###xml 152 161 149 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g001">Figure 1A</xref>
###xml 322 334 319 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g001">Figure 1B, C</xref>
###xml 352 367 349 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006743.s001">Figure S1A, S1B</xref>
###xml 688 697 685 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g001">Figure 1D</xref>
###xml 852 861 849 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g001">Figure 1E</xref>
###xml 959 968 956 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g001">Figure 1E</xref>
###xml 1055 1064 1052 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g001">Figure 1E</xref>
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
###xml 59 65 <span type="species:ncbi:9986">rabbit</span>
###xml 107 110 <span type="species:ncbi:10116">rat</span>
###xml 140 144 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 189 194 <span type="species:ncbi:10090">mouse</span>
###xml 212 215 <span type="species:ncbi:10116">rat</span>
###xml 392 395 <span type="species:ncbi:10116">rat</span>
###xml 413 418 <span type="species:ncbi:10090">mouse</span>
###xml 577 582 <span type="species:ncbi:10090">mouse</span>
###xml 587 590 <span type="species:ncbi:10116">rat</span>
###xml 674 679 <span type="species:ncbi:10090">mouse</span>
###xml 1049 1053 <span type="species:ncbi:10116">rats</span>
###xml 1219 1223 <span type="species:ncbi:10116">rats</span>
###xml 1225 1228 <span type="species:ncbi:10116">SHR</span>
We constructed a transgene using the mouse MLC-2 promoter, rabbit beta-globin exon 2, intron 2 and exon 3, rat CTGF cDNA and a polyA signal SV40-virus (Figure 1A). We obtained a transgenic mouse and a transgenic rat line, which showed an abundant expression of CTGF mRNA and protein in the heart but not in other tissues (Figure 1B, C and supplemental Figure S1A, S1B). The overexpression of rat CTGF cDNA in the mouse allowed us to distinguish between endogenous CTGF expression and CTGF mRNA derived from the transgene. As shown by quantitative Taqman-PCR with specific CTGF mouse and rat primers and probes, the endogenous CTGF expression was strongly induced in CTGF-TG mouse hearts (Figure 1D) indicating an autocrine mechanism driving the CTGF expression in the heart. As shown by immunohistochemistry CTGF was marginally expressed in WT hearts (Figure 1E) while in the transgenic heart ventricles CTGF was abundantly present in the interstitial space (Figure 1E). No CTGF specific staining signal was observed in non-hypertensive WKY-control rats (Figure 1E) or in control staining performed without primary anti-CTGF-antibody (data not shown). In comparison, hearts from 6-months-old spontaneously hypertensive rats (SHR) displayed a pronounced hypertrophy and fibrosis accompanied by high CTGF upregulation with a similar localization in the interstitial space (data not shown).
###end p 8
###begin title 9
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Construction of cardiomyocyte-specific CTGF-TG mice.
###end title 9
###begin p 10
###xml 218 224 <span type="species:ncbi:9986">rabbit</span>
###xml 292 296 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 329 344 <span type="species:ncbi:10633">Simian virus 40</span>
###xml 438 453 <span type="species:ncbi:10090">transgenic mice</span>
###xml 562 567 <span type="species:ncbi:10090">mouse</span>
###xml 801 805 <span type="species:ncbi:10090">mice</span>
###xml 833 837 <span type="species:ncbi:10116">rats</span>
###xml 886 889 <span type="species:ncbi:10116">rat</span>
###xml 891 894 <span type="species:ncbi:10116">SHR</span>
(A) Schematic structure of the transgene. 1 and 2 indicate primers used for genotyping and 3 and 4 show primers used to generate the probe for CTGF ribonuclease protection assay. MLC-2 (myosin light chain-2) promoter; rabbit beta-globin exon 2 and 3 for enhanced expression of the transgene; SV40 pA, polyadenylation signal from Simian virus 40. (B) Expression of CTGF mRNA in hearts (He) and other organs (kidney, lung, liver, brain) of transgenic mice shown by ribonuclease protection assay. (C) Western Blot analyses of CTGF protein overexpression in CTGF-TG mouse hearts. GAPDH protein expression was used as loading control. (D) Quantification of the transgenic and endogenous CTGF mRNA expression by TaqMan PCR. (WT n = 4, TG n = 4; *, P<0.05 (E) Histological staining of CTGF in WT and CTGF-TG mice as well as in Wistar-Kyoto rats (WKY) as control for spontaneously hypertensive rat (SHR). Scale bars designate a length of 100 microm.
###end p 10
###begin title 11
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Age-dependent heart failure in CTGF-TG mice
###end title 11
###begin p 12
###xml 186 195 186 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g002">Figure 2D</xref>
###xml 302 311 302 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g002">Figure 2A</xref>
###xml 796 805 796 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g002">Figure 2B</xref>
###xml 954 963 954 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g002">Figure 2C</xref>
###xml 1031 1044 1031 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g002">Figure 2C, 2D</xref>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 17 21 <span type="species:ncbi:10116">rats</span>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 486 501 <span type="species:ncbi:10090">transgenic mice</span>
###xml 895 899 <span type="species:ncbi:10090">mice</span>
CTGF-TG mice and rats developed normally and had no immediate increased mortality. To investigate the role of CTGF in cardiac performance we examined mice by echocardiography over time (Figure 2D). At 3 months of age, the average LVEDD and LVESD as well as FS were similar in control and CTGF-TG mice (Figure 2A). Compensatory hypertrophy, dilatation, and finally loss of contractility became apparent at a later age. At age of 4 months, the LVEDD reached an average value of 3.9 mm in transgenic mice, compared to 4.2 mm in normal littermates (p<0.01). Similarly, a reduction of LVESD and an increase of PWTD, both significant, were observed indicating a hypertrophic change in the left heart chamber architecture. These changes were associated with a slight but not significant increase in FS (Figure 2B). Hypertrophy was followed by ventricular dilatation at the age of 7 months: the CTGF-TG mice developed remarkably increased ventricular diameters (Figure 2C) and a severe loss of the cardiac function compared to WT animals (Figure 2C, 2D). Thus, CTGF overexpression in cardiomyocytes caused age-dependent heart dysfunction with a disease course going from compensatory hypertrophy to ventricular dilatation and systolic heart failure.
###end p 12
###begin title 13
###xml 28 32 <span type="species:ncbi:10090">mice</span>
Characterization of CTGF-TG mice of different ages by echocardiography.
###end title 13
###begin p 14
###xml 93 97 <span type="species:ncbi:10090">mice</span>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 304 308 <span type="species:ncbi:10090">mice</span>
(A, B, C) Measurements of LVEDD, LVESD, calculated ratio of PWD/LVEDD and FS of 3-months-old mice (A, WT n = 9 TG n = 7), 4-months-old mice (B, WT n = 10, TG n = 9) and 7-months-old mice (C, WT n = 7, TG n = 6). * P<0.05; ** P<0.01; *** P<0.001. (D) Examples of M-mode echocardiography in CTGF-TG and WT mice at age of 7 months.
###end p 14
###begin title 15
###xml 41 47 <span type="species:ncbi:10090">murine</span>
###xml 51 54 <span type="species:ncbi:10116">rat</span>
CTGF does not induce cardiac fibrosis in murine or rat hearts
###end title 15
###begin p 16
###xml 278 287 278 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g003">Figure 3A</xref>
###xml 305 323 305 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006743.s001">Figure S1C and S1E</xref>
###xml 448 461 444 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g003">Figure 3B, 3C</xref>
###xml 479 489 475 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006743.s001">Figure S1D</xref>
###xml 634 643 630 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g003">Figure 3D</xref>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 177 181 <span type="species:ncbi:10116">rats</span>
###xml 433 437 <span type="species:ncbi:10090">mice</span>
###xml 442 446 <span type="species:ncbi:10116">rats</span>
###xml 522 528 <span type="species:ncbi:10090">murine</span>
###xml 628 632 <span type="species:ncbi:10090">mice</span>
###xml 738 744 <span type="species:ncbi:10090">murine</span>
###xml 752 755 <span type="species:ncbi:10116">rat</span>
Since a large body of evidence implicates CTGF as a profibrotic factor, we addressed the question whether CTGF overexpression would induce cardiac fibrosis. In CTGF-TG mice and rats no fibrotic changes were detectable as assessed by Masson's trichrome and Sirius red stainings (Figure 3A and supplemental Figure S1C and S1E). Accordingly, the mRNA levels of collagen 1alpha, collagen 3, and fibronectin were not increased in CTGF-TG mice and rats (Figure 3B, 3C and supplemental Figure S1D). Yet, an increased diameter of murine CTGF-TG cardiomyocytes could be detected by tissue structural analyses in hearts from 7 months old mice (Figure 3D). Taken together, overexpression of CTGF in cardiomyocytes did not induce fibrosis neither in murine nor in rat hearts, but was rather associated with hypertrophic changes at the cellular level.
###end p 16
###begin title 17
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Assessment of cardiac fibrosis at age of 4 and 7 months in CTGF-TG and WT mice.
###end title 17
###begin p 18
###xml 66 70 <span type="species:ncbi:10090">mice</span>
(A) Masson's trichrome stained cardiac sections of WT and CTGF-TG mice at age of 4 and 7 months. Scale bars designate a length of 100 microm. (B, C) Quantification of the collagen 1alpha, collagen 3 and fibronectin mRNA expression by TaqMan-PCR performed at age of 4- (B) and 7 months (C) (n = 4 per group). (D) High magnifications of toluidine blue-stained semithin sections, with myofiber hypertrophy apparent in 7 months old CTGF-TG hearts. Scale bars designate a length of 20 microm.
###end p 18
###begin title 19
CTGF overexpression is associated with Akt- and JNK-activation
###end title 19
###begin p 20
###xml 353 369 353 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g004">Figure 4A and 4B</xref>
###xml 558 567 558 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g004">Figure 4C</xref>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 311 326 <span type="species:ncbi:10090">transgenic mice</span>
###xml 498 504 <span type="species:ncbi:10090">murine</span>
###xml 683 698 <span type="species:ncbi:10090">transgenic mice</span>
To elucidate the cellular mechanisms underlying the observed phenotype in CTGF-TG mice, we determined the mRNA expression levels of two hypertrophy markers, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). TaqMan real time PCR showed no changes in the ANP and BNP expression between WT and transgenic mice at 4 and 7 months of age (Figure 4A and 4B). To further examine whether CTGF initiates hypertrophic signals immunoblot analyses were performed on lysates from 7-month-old murine hearts with phospho-specific antibodies. As shown in Figure 4C CTGF-TG hearts displayed an activation of the Akt and JNK pathways. These data suggest that the cardiac changes in transgenic mice were associated with the activation of the Akt and JNK pathways but were independent of ANP and BNP expression.
###end p 20
###begin title 21
Quantification of expression and activation of cardiac hypertrophy markers.
###end title 21
###begin p 22
###xml 98 102 <span type="species:ncbi:10090">mice</span>
(A, B) Quantification of ANP and BNP mRNA expression by TaqMan-PCR in 4- (A) and 7 months (B) old mice (n = 4 per group). (C) Quantitative analysis of the phosphorylation status of Akt and JNK at age of 7 months. The band intensities of Akt- or JNK-phosphoproteins are normalized with those of unphosphorylated Akt or unspecific bands respectively.
###end p 22
###begin title 23
CTGF overexpression preserves the cardiac function under Ang II-induced pressure overload conditions
###end title 23
###begin p 24
###xml 136 145 136 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g005">Figure 5A</xref>
###xml 223 232 223 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g005">Figure 5A</xref>
###xml 431 440 431 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g005">Figure 5B</xref>
###xml 640 649 640 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g005">Figure 5C</xref>
###xml 798 807 794 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g005">Figure 5C</xref>
###xml 926 935 922 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006743-g005">Figure 5D</xref>
###xml 6 10 <span type="species:ncbi:10090">mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 323 327 <span type="species:ncbi:10090">mice</span>
###xml 510 514 <span type="species:ncbi:10090">mice</span>
###xml 621 625 <span type="species:ncbi:10090">mice</span>
###xml 1008 1012 <span type="species:ncbi:10090">mice</span>
In WT mice, echocardiography revealed a significant reduction in systolic function after Ang II infusion, as indicated by decreased FS (Figure 5A). This reduction was almost completely abrogated in treated CTGF-TG animals (Figure 5A). In CTGF-TG mice, the contractile performance after Ang II was preserved to the level of mice receiving only a sham infusion. As expected after Ang II infusion, the ratio PWTD/LVEDD was increased (Figure 5B). However, these increases were not different between WT and CTGF-TG mice. The subsequent stainings showed an increased degree of fibrosis, which was not different between CTGF-TG mice and controls (Figure 5C). Accordingly, collagen 1alpha mRNA was elevated in WT and transgenic animals after treatment with Ang II, but both groups were similarly affected (Figure 5C). The mRNA quantification of the hypertrophy markers ANP and BNP showed a significant increase after Ang II infusion (Figure 5D). However, there were no significant differences between CTGF-TG and WT mice. Altogether, these data suggest that CTGF overexpression has a beneficial effect on cardiac function in an acute pressure-overload heart failure model. This protection is not due to elevated levels of ANP and BNP. Moreover, the CTGF overexpression does not affect the development of cardiac fibrosis under hypertrophic conditions.
###end p 24
###begin title 25
Characterisation of cardiac function, fibrosis and hypertrophy under pressure overload conditions (3.5 months of age).
###end title 25
###begin p 26
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
(A, B) Echocardiographic measurements of fractional shortening (A) and interventricular septum diameter in diastole (B) in WT (n = 10) and CTGF-TG (n = 11) mice treated with Ang II (*p<0.05; ** p<0.01, *** p<0.001) (C) Masson's trichrome stained cardiac sections of mice treated with Ang II and quantification of collagen 1alpha mRNA expression by Taqman-PCR. (D) Quantification of ANP and BNP mRNA expression by TaqMan-PCR in mice treated with Ang II (n = 4 per group).
###end p 26
###begin title 27
###xml 11 13 11 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Improved Ca2+ handling in CTGF TG cardiomyocytes
###end title 27
###begin p 28
###xml 120 122 120 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 369 378 369 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006743.s002">Figure S2</xref>
###xml 491 505 491 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006743.s002">Figure S2A-S2D</xref>
###xml 547 549 547 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 593 595 593 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 675 677 675 677 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 762 776 762 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006743.s002">Figure S2E-S2H</xref>
###xml 839 841 839 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 912 914 912 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 957 959 957 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1183 1185 1183 1185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1268 1270 1268 1270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
To further elucidate the cellular mechanisms in CTGF-TG hearts at a single cell level, we characterized intracellular Ca2+ transients of isolated cardiomyocytes. The recordings of contraction kinetics of single cardiomyocytes at 3 months of age revealed that the basal cell length and contractile function were similar in transgenic and WT cardiomyocytes (supplemental Figure S2). In both groups, we observed a comparable FS as well as similar contraction and relaxation rates (supplemental Figure S2A-S2D). In order to record the intracellular Ca2+-transient, we loaded cardiomyocytes with Ca2+-sensitive Fura-2 dye and observed a slightly, but robustly reduced cytosolic Ca2+-content in diastole in transgenic cardiomyocytes compared to WT cells (supplemental Figure S2E-S2H). These results indicate an improved diastolic clearance of Ca2+ from the cytosol in CTGF-TG cardiomyocytes. Further, we assayed the Ca2+ transient amplitude and the velocity of Ca2+ influx and -efflux from sarcoplasmatic reticulum. Yet, the last parameters were not found to be changed in transgenic cardiomyocytes. Taken together, overexpression of CTGF in cardiomyocytes is accompanied by an enhanced Ca2+ clearance from the cytosol. However, at this time point the modification of the Ca2+ cycling is not reflected in an altered cellular contractility.
###end p 28
###begin title 29
CTGF-overexpression and acute ischemia
###end title 29
###begin p 30
###xml 74 78 74 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Gabrielsen1">[23]</xref>
###xml 80 84 80 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Ahmed1">[24]</xref>
###xml 631 649 631 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006743.s003">Figure S3A and S3B</xref>
###xml 743 761 743 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006743.s003">Figure S3C and S3D</xref>
###xml 208 213 <span type="species:ncbi:10090">mouse</span>
Several studies reported an upregulation of CTGF upon ischemic conditions.[23], [24] In order to examine the effects of CTGF overexpression on the ischemic heart disease, we subjected isolated CTGF-TG and WT mouse hearts to 40 minutes ischemia with subsequent 60 minutes reperfusion phase. In the setting of the working heart model, we monitored the left ventricular pressures and contraction- and relaxation rates at baseline as well as after ischemia and reperfusion. Interestingly, the CTGF-TG and WT hearts displayed similar intracardiac pressures under basal conditions as well as under ischemia and reperfusion (supplemental Figure S3A and S3B). Similar results were obtained in respect to contraction and relaxation rates (supplemental Figure S3C and S3D). All together, these data suggest, that CTGF overexpression does not play a role in the immediate physiological response of the heart to ischemia. In addition, the acute recovery process is not affected by CTGF overexpression.
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 1013 1017 1013 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Yokoi1">[15]</xref>
###xml 1112 1116 1112 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Riser1">[25]</xref>
###xml 12 27 <span type="species:ncbi:10090">transgenic mice</span>
###xml 32 36 <span type="species:ncbi:10116">rats</span>
###xml 196 211 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 216 220 <span type="species:ncbi:10116">rats</span>
###xml 479 483 <span type="species:ncbi:10116">rats</span>
###xml 731 736 <span type="species:ncbi:10090">mouse</span>
We produced transgenic mice and rats with cardiomyocyte-restricted overexpression of CTGF and found that CTGF alone does not induce cardiac fibrosis, but rather exerts a prohypertrophic function. Transgenic mice and rats abundantly expressed the CTGF protein in the interstitial space of the right and left ventricles. The secretion of CTGF from cardiomyocytes to the interstitium is in accordance with the localization of CTGF observed in hearts from spontaneously hypertensive rats, another model with significant CTGF upregulation. These findings confirm the physiological distribution of transgenic CTGF and support the suitability of our models for the analysis of CTGF function in the heart. Moreover, we observed in CTGF-TG mouse hearts an increased expression of the endogenous mRNA, which points to an autocrine enhancement of the CTGF regulation. This finding mirrors data published by Yokoi and colleagues, demonstrating an increased endogenous CTGF expression in kidney overexpressing transgenic CTGF [15]. Furthermore, CTGF administration also stimulates CTGF expression in cultured mesangial cells [25].
###end p 32
###begin p 33
###xml 720 724 713 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Yokoi1">[15]</xref>
###xml 981 985 974 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Bonniaud1">[26]</xref>
###xml 1771 1775 1758 1762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Mori1">[27]</xref>
CTGF is felt to be one of the key profibrotic factors mediating the TGF-beta profibrotic action. Surprisingly, the overexpression of CTGF in cardiomyocytes did not result in increased development of cardiac fibrosis neither under basal nor under hypertrophic conditions. We carefully assayed the development of fibrosis in both transgenic models by use of various methods. Our morphological observations were confirmed by collagen 1alpha, collagen 3, and fibronectin mRNA quantification, which also did not reveal significant changes between WT and transgenic hearts. These findings are in line with results obtained from CTGF overexpression in kidney, which also did not result in renal fibrosis under basal conditions [15]. Even after induction of diabetes in this model, no changes in the expression level of key ECM inducers like fibronectin, collagen 4A1 and 4A3 were detected. Benniaud and colleagues transiently overexpressed CTGF in lung using the adenoviral gene transfer [26]. In their study, a drastic CTGF overexpression induced a moderate pulmonary fibrosis suggesting CTGF as an indirect profibrotic factor. The cell type overexpressing CTGF may play a crucial role in the observed phenotype. Despite cardiomyocyte specific CTGF overexpression, we believe, that secretion of the protein allows it to exert its physiological function also on cardiac fibroblasts. It would be certainly intriguing to overexpress CTGF specifically in cardiac fibroblasts; however, a specific promoter for this cell type is not available until now. Interestingly, Mori at al. tested the fibrotic response of CTGF-null embryonic fibroblasts upon TGF-beta stimulation. This study revealed CTGF to be dispensable for the TGF-beta induced fibrotic response in embryonic fibroblasts [27]. In conclusion, our results and other studies support the hypothesis, that CTGF itself is not a fibrosis inducer. However, the protein may play a role as a profibrotic cofactor under certain conditions.
###end p 33
###begin p 34
###xml 554 562 554 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 562 566 562 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Hayata1">[21]</xref>
###xml 1011 1015 1011 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Shiojima1">[28]</xref>
###xml 1219 1223 1219 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Shiojima1">[28]</xref>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
Given the possibility that CTGF is involved in contractile function and hypertrophy, we examined CTGF-TG mice by echocardiography. We observed an age dependent presence of cardiac hypertrophy, which was followed by ventricular dilatation at the age of 7 months. This phenotype was accompanied by an increased activation of the prohypertrophic Akt Kinase but surprisingly not by an increase of ANP and BNP expression. These findings are consistent with data published by Hyata et al., who showed hypertrophic effects of CTGF stimulation on cardiomyocytes in vitro[21]. The authors also demonstrated that hypertrophic changes of cultured cardiomyocytes were accompanied by upregulation of skeletal actin and BNP when induced by endothelin-1, but not after stimulation with CTGF. Furthermore, the study showed, that Akt activation is required for CTGF-mediated induction of hypertrophy. Interestingly, recent studies have demonstrated that Akt plays an important role in the determination of cardiac myocytes size [28]. Recently, transient activation of Akt in the heart was reported to result in adaptive/physiological hypertrophy while longer periods of Akt activation were detrimental and led to dilated cardiomyopathy [28]. These observations provide a possible explanation for the disease course observed in our CTGF-TG model. While the initial overexpression of CTGF activates Akt triggering adaptive hypertrophy, the prolonged CTGF overexpression tips the balance towards heart failure.
###end p 34
###begin p 35
###xml 350 354 <span type="species:ncbi:10090">mice</span>
If overexpression of CTGF initially enhances cardiac adaptive response, the CTGF overexpressing hearts should display improved remodeling in acute cardiomyopathy. To test this hypothesis, we employed infusion of Ang II for 14 days as a model of acute pressure overload. In fact, echocardiography revealed a strong decrease of systolic function in WT mice, while CTGF-TG hearts showed preserved cardiac function that was similar to that of sham-treated animals. These results suggest a role of CTGF in the induction of cardiac adaptive response and its function as a protective factor in acute cardiomyopathy. An interpretation of these results is that CTGF plays a role as an early prohypertrophic factor that mildens or delays heart failure by reducing transmural wall tension. Such an adaptive hypertrophic response would transiently improve cardiac performance. However, in the course of progressive heart failure, the continuous expression of CTGF becomes enhanced through autocrine and paracrine regulation triggering an increased activation of prohypertrophic pathways like the Akt kinase pathway. Thus, a certain basal CTGF expression might have a beneficial effect on cardiac performance while long-term CTGF upregulation leads to "overstimulation" and activation of pathological pathways resulting in loss of cardiomyocytes and ventricular dilatation.
###end p 35
###begin p 36
###xml 93 95 93 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 269 271 269 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 430 432 430 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Bers1">[29]</xref>
###xml 479 481 479 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 529 531 529 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 619 621 619 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 644 646 644 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 822 824 822 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 895 897 895 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1001 1003 1001 1003 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1129 1131 1129 1131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1160 1162 1160 1162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1228 1230 1228 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1264 1265 1264 1265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1268 1270 1268 1270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1281 1285 1281 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Piacentino1">[30]</xref>
###xml 1353 1355 1353 1355 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
The altered contractile performance of CTGF-TG hearts may also be attributed to a modified Ca2+ handling in cardiomyocytes. To get a comprehensive picture of the cellular mechanisms accompanying the phenotypical changes in CTGF overexpressing hearts, we analyzed the Ca2+ metabolism and cardiomyocyte mechanisms at single cell level. Myocyte contraction and relaxation are under the control of the rise and decline in cytosolic Ca2+ levels [29]. The rise in intracellular free Ca2+ initiates contraction through the binding of Ca2+ to myofilaments, whereas myocyte relaxation is promoted by decrease in intracellular Ca2+ and dissociation of Ca2+ from the myofilaments. Although the cellular contractility at age of 3 months did not differ between the CTGF-TG and WT cardiomyocytes, we observed an increased reuptake of Ca2+ from the cytosol in CTGF-TG myocytes. A consequence of an increased Ca2+ reuptake might be an enhanced contractile function. However, we suggest that the observed changes in Ca2+ metabolism may promote increased contractility under stress conditions like upon Ang II stimulation. Lowering in cytosolic Ca2+ is accomplished mainly by Ca2+ sequestration into the sarcoplasmatic reticulum by SERCA2a and Ca2+ extrusion from the cell by the Na+/Ca2+-Exchanger [30]. To elucidate the contribution of both pathways to the increased Ca2+ reuptake in CTGF overexpressing cardiomyocytes, further experiments need to be done.
###end p 36
###begin p 37
###xml 197 201 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Gabrielsen1">[23]</xref>
###xml 203 207 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Ahmed1">[24]</xref>
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Dean1">[31]</xref>
###xml 895 899 895 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-Dean1">[31]</xref>
Several studies implicate CTGF as a factor being involved in tissue remodeling after myocardial infarction, but its physiological function in ischemia and following muscle recovery remains elusive [23], [24], [31]. Therefore, the present study also focused on this functional aspect of CTGF. In the working heart model we observed a similar reduction of contractility under ischemic conditions in CTGF-TG and WT hearts. Moreover, the recovery of contractile function after reperfusion was comparable in both groups. These results suggest that CTGF does not play an immediate physiological role in acute ischemic and postischemic events. We rather assume that CTGF exerts its function in later postischemic phase, where its expression is strongly induced. Dean et al. reported on major increases in CTGF mRNA and protein occurring in the viable myocardium at 180 days after myocardial infarction [31].
###end p 37
###begin p 38
###xml 187 189 187 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 287 294 287 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
In summary, our current study presents evidence that CTGF itself does not induce fibrosis, but rather is a protein involved in adaptive cardiac mechanisms like cellular hypertrophy and Ca2+ metabolism modification. Although CTGF is broadly accepted as a profibrotic factor, there are no in vivo studies showing a clear causality between CTGF overexpression and fibrosis induction. So far, the major evidence for the profibrotic action of CTGF is based on the fact, that fibrotic events are accompanied by CTGF upregulation. Thus, we believe that our data provide good reason to reconsider the profibrotic role of CTGF particularly in the heart shedding new light on the functional diversity of this protein. However, detailed mechanisms of CTGF action will require further studies.
###end p 38
###begin title 39
Materials and Methods
###end title 39
###begin title 40
###xml 19 34 <span type="species:ncbi:10090">transgenic mice</span>
Generation of CTGF-transgenic mice (CTGF-TG)
###end title 40
###begin p 41
###xml 41 44 <span type="species:ncbi:10116">rat</span>
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
We generated cardiac-directed transgenic rat (Sprague-Dawley) and mouse (FVB/N).
###end p 41
###begin p 42
###xml 68 101 68 101 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-cggaattcgctgtgcgtcctcctgccg-3&#8242;</named-content>
###xml 106 140 106 140 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-cgggatccgagttcgtgtcccttactcc-3&#8242;</named-content>
###xml 420 424 417 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006743-ReRN1">[32]</xref>
###xml 527 557 524 554 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-atgttatatggagggggcaaagtt-3&#8242;</named-content>
###xml 562 585 559 582 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-tccacgccagccagaat-3&#8242;</named-content>
###xml 16 19 <span type="species:ncbi:10116">rat</span>
###xml 182 187 <span type="species:ncbi:10090">mouse</span>
###xml 246 252 <span type="species:ncbi:9986">rabbit</span>
###xml 385 390 <span type="species:ncbi:10090">mouse</span>
###xml 395 398 <span type="species:ncbi:10116">rat</span>
The full-length rat CTGF cDNA was amplified with following primers (5'-cggaattcgctgtgcgtcctcctgccg-3' and 5'-cgggatccgagttcgtgtcccttactcc-3') and cloned into a vector containing the mouse myosin light chain-2 promoter (MLC-2) and a region of the rabbit beta-globin gene containing exon 2, intron 2 and exon 3. The construct was linearized and microinjected into the male pronucleus of mouse and rat zygotes as described [32]. The identification of founder animals and further genotyping were conducted by PCR using the primers 5'-atgttatatggagggggcaaagtt-3' and 5'-tccacgccagccagaat-3'. Animals were kept in the hemizygote state. All animals used in this study were males. All experimental protocols were performed in accordance with the guidelines for the humane use of laboratory animals by the Max-Delbruck Center for Molecular Medicine and were approved by local German authorities with standards corresponding to those prescribed by the American Physiological Society.
###end p 42
###begin title 43
Echocardiography and Angiotensin II (Ang II) infusion
###end title 43
###begin p 44
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
A two-dimensional short axis view of the left ventricle was obtained with a 45-MHz transducer (Sonic Vevo 770 High-Resolution Imaging System, Toronto, Canada) from Isofluran anesthetized mice. M-mode tracings were recorded and used to determine the diameter of the left ventricle at the end of the diastole (LVEDD) and systole (LVESD). Fractional shortening (FS) corresponds to the value of (LVEDD-LVESD)/LVEDD. In 3.5-months-old mice we infused Ang II (1.4 mg/kg/day) for 14 days by Alzet osmotic pumps (Alzet, Cupertino, USA) implanted subcutaneously. All animal studies were carried out in accordance with the local authorities and conforming to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
###end p 44
###begin title 45
Analysis of mRNA Expression
###end title 45
###begin p 46
###xml 166 168 166 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 185 193 185 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 946 961 942 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;&#916;&#916;CT)</sup>
Total RNA was extracted from organs by using TRIzol reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, USA). An antisense probe for CTGF was 32P-UTP-labeled by in vitro transcription (Riboprobe combination system Sp6/T7; Promega, Madison, USA). RNA expression was measured by RNase protection assay (RPA II kit, Ambion, Austin, USA). Protected fragments were separated on a polyacrylamide gel and detected with a Fuji phospho-imager (Fujix BAS 2000, Fuji, Tokyo, Japan). The quantification of ANP, BNP, collagen 1alpha, collagen 3, fibronectin, and GAPDH was carried out by Taqman-PCR. The total RNA was reverse-transcribed with oligo(dT) primers (Gibco-BRL, Carlsbad, USA) and Omniscript reverse transcriptase (Qiagen, Hilden, Germany). Primers and probes were designed using Primer Express 2.0 (Applied Biosystems, Foster City, USA). Expression levels of all genes were normalized to GAPDH RNA expression by using the 2(-DeltaDeltaCT) method. To compare samples the DeltaCt-mean of the wild type group was used as a calibration sample.
###end p 46
###begin title 47
Histological Analysis
###end title 47
###begin p 48
###xml 385 386 381 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 478 479 474 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 928 934 <span type="species:ncbi:9793">donkey</span>
###xml 1167 1171 <span type="species:ncbi:9925">goat</span>
Hearts from 4- or 7-months-old CTGF-TG or control animals were perfused with 4% paraformaldehyde and embedded in paraffin. Longitudinal sections (10 microm) were stained with Masson's trichrome and Sirius red. For high magnification pictures heart tissue was perfused with 4% paraformaldehyde and postfixed with 2.5% glutaraldehyde in PBS for 48 hours. Samples were stained with 1% OsO4 for 2 h, dehydrated in a graded ethanol series and propylene oxide and embedded in Poly/BedR 812 (Polysciences, Inc., Eppelheim, Germany). Semithin sections (1 microm) from 7 months old animals were stained with toluidine blue. For CTGF-specific staining, hearts were cryo-preserved, cut in longitudinal sections (8 microm) and mounted onto SuperFrost Plus slides (Menzel, Braunschweig, Germany). The sections were fixed with cold acetone, washed with TBS, and incubated for 30 minutes in a humid chamber at room temperature with 10% normal donkey serum (Jackson ImmunoResearch, West Grove, USA) and washed again with TBS. Subsequently sections were incubated for 60 minutes with polyclonal anti-CTGF primary antibody (1:500; Santa Cruz, Santa Cruz, USA). The Cy3-conjugated anti-goat IgG was uses as secondary antibody (1:500; Jackson ImmunoResearch, West Grove, USA). Fluorescence images were collected using Axioplan2 imaging microscope and a Sensicam 12BIT camera (Zeiss, Jena, Germany).
###end p 48
###begin title 49
Western Blot
###end title 49
###begin p 50
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Hearts from 7-months-old CTGF-TG and control mice were homogenized in RIPA-protein extraction buffer and denatured in SDS-loading buffer (Roth, Karlsruhe, Germany) at 95degreesC for 5 minutes. SDS-PAGE was carried out and blotted on PVDF-membranes (Amersham, Little Chalfon, UK). Membranes were blocked with 5% (w/v) dried milk in 100 mmol/L Tris, pH 7.5, 0.1% (v/v) Tween 20 and 150 mmol/L NaCl (TBST) for 1 h prior to overnight incubation at 4degreesC with anti-CTGF, anti-phospho-Akt or anti-phospho-JNK (Cell Signaling, Danvers, USA) antibody as a first antibody. To quantify the extend of Akt phosphorylation and CTGF expression, the membrane was reprobed with anti-Akt antibody (Cell Signaling, Danvers, USA) or anti-GAPDH, respectively. The band intensities of Akt-phospho-protein were normalized with those of total Akt-protein. The level of JNK phosphorylation was normalized for band intensities of unspecific bands. The expression of CTGF was normalized with GAPDH expression.
###end p 50
###begin title 51
Working heart model
###end title 51
###begin p 52
###xml 417 418 417 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 428 429 428 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 440 441 440 441 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 461 462 461 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
Three months old mice were anaesthetized with 4% chloralhydrate (Sigma Aldrich, Taufkirchen, Germany) and injected with 5,000 U/kg heparin. After thoracotomy, hearts were quickly removed, the aorta cannulated, and connected to the perfusion apparatus (Hugo Sachs electronic, March-Hugstetten, Germany). They were perfused retrogradally with Krebs-Henseleit solution (KH; mM concentrations: 118 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSo4, 1.2 KH2PO4, 0.5 EDTA, 25 NaHCO3, 5.5 glucose, pH 7.4, 37degreesC) with a constant pressure of 50 mmHg (Langendorff mode). A Millar tip catheter was inserted into the left ventricle for measurements of pressure development and its derivatives. A small catheter was placed into the left atrium through the pulmonary vein for perfusion of the left atrium with KH at constant pressure of 10-11 mmHg (flow around 5 mL/min; preload). Registration was than switched from retrograde to anterograde perfusion (working heart mode). The perfusate exited the left ventricle through the aortic cannula, which was connected to a pressure chamber with an air cushion for the windkessel function. Aortic pressure was set to 50 mmHg (afterload). The heart was electrically paced with a constant frequency of 320 beats/min and was subjected to 40 minutes baseline perfusion, 40 minutes ischemia followed by 60 minutes reperfusion. Recordings were performed in the last 7 minutes of each phase. Signals were recorded, stored, and evaluated using software HEM (version 3.2, Notocord System).
###end p 52
###begin title 53
Isolation of adult primary cardiomyocytes
###end title 53
###begin p 54
###xml 381 383 367 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 446 447 432 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 449 450 435 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 462 463 448 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 473 474 459 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1037 1039 1007 1009 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1055 1057 1025 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1134 1136 1100 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 708 714 <span type="species:ncbi:9913">bovine</span>
###xml 1252 1258 <span type="species:ncbi:9913">bovine</span>
###xml 1283 1287 <span type="species:ncbi:9913">calf</span>
Male wild-type or CTGF-TG mice (3-months-old) were anaesthetized with isoflurane followed by intraperitoneal injection of 8 microg xylazine and 35 microg ketamine. Hearts were rapidly removed, transferred into 10 ml 0.9% NaCl solution containing 1,000 U heparin, and connected to a cannula in a Langendorff perfusion system. Hearts were perfused at 37degreesC for 3 minutes with Ca2+-free Krebs-Henseleit buffer (KHB: 127 mM NaCl, 4.6 KCl, 1.2 KH2PO4, 24.8 NaHCO3, 1.1 MgSO4, 8.3 glucose, 10 butanedione monoxime, pH 7.4, 37degreesC) gassed with carbogen. After that, perfusion was switched to recirculation with KH containing 0.04% collagenase (Worthington Biochemical Corporation, Lakewood, USA), and 0.2% bovine serum albumin. After 27 minutes, the hearts were pale and soft. The ventricles were minced and incubated in the digestion medium (0,23% BSA, 0.04% collagenase in KH solution) for another 10 minutes at 37degreesC. After filtration through a nylon mesh (200 microm pore size) and centrifugation, cells were resuspended in Ca2+-free medium. Ca2+ concentration was increased stepwise to 500 micromol/L in order to obtain Ca2+-tolerant cardiomyocytes. After final washes, cardiomyocytes were resuspended in M199 medium supplemented with 0.2% bovine serum albumin, 5% fetal calf serum, 5 mmol/L creatine, 5 mmol/L taurine, 2 mmol/L carnitine, 10 micromol/L cytosine-D-arabinofuranoside, and antibiotics. Cardiomyocytes were seeded in laminin-coated 4-well chamber slides (Nunc, Wiesbaden-Schierstein, Germany) specialized for microscopic contractility and fluorescence measurement, and cultured for 4 hours in M199 medium.
###end p 54
###begin title 55
###xml 32 34 32 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Measuring cell shortening and Ca2+ transients
###end title 55
###begin p 56
###xml 674 676 668 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Attached cardiomyocytes were washed with Hank's balanced salts solution buffered with 10 mM Hepes at pH 7.4 (HBSS). Cells were loaded with fura-2-AM for 30 minutes at room temperature in the dark. Dye solution was removed, and cells were left on HBSS for another 15 minutes. Cell shortening and fura-signals were simultaneously measured at 30degreesC on an Ionoptix contractility and fluorescence system (Ionoptix, Milton, USA). Cardiomyocytes were electrically field-stimulated with bipolar pulses of 5 ms duration at 1 Hz. Cell shortening, expressed as percentage of resting cell length, was measured using the video-edge technique at a sampling rate of 240 per second. Ca2+ transients were monitored as ratio of fluorescence emission at 510 nm obtained by alternate excitation at 340 and 380 nm (340/380 ratio). Data files from 15 consecutive beats recorded at intervals were averaged for analysis.
###end p 56
###begin title 57
Statistical analysis
###end title 57
###begin p 58
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Differences between two groups were evaluated by using unpaired Student's t-test and Mann-Whitney U-test. Differences between more than two groups were evaluated by using ANOVA followed by Fisher's probable least-squares difference test using Prism software (Graphpad Software, La Jolla, USA). The significance level was set at p<0.05. All data are expressed as mean+/-SEM.
###end p 58
###begin title 59
Supporting Information
###end title 59
###begin p 60
###xml 32 36 <span type="species:ncbi:10116">rats</span>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 98 102 <span type="species:ncbi:10116">rats</span>
###xml 211 214 <span type="species:ncbi:10116">rat</span>
###xml 356 359 <span type="species:ncbi:10116">rat</span>
###xml 386 389 <span type="species:ncbi:10116">rat</span>
###xml 545 549 <span type="species:ncbi:10116">rats</span>
###xml 627 631 <span type="species:ncbi:10090">mice</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
###xml 727 732 <span type="species:ncbi:10090">mouse</span>
Fibrosis development in CTGF-TG rats and mice. (A) Expression of CTGF mRNA in heart of transgenic rats shown by ribonuclease protection assay. (B) Western Blot analyses of CTGF protein overexpression in CTGF-TG rat hearts. GAPDH protein expression was used as loading control. (C) Sirius red staining of fibrotic tissue in left ventricle of WT and CTGF-TG rat as well as CTGF-TG and WT rat treated with isoproterenol. (D) Quantification of the collagen 1alpha, collagen 3, and fibronectin mRNA expression by TaqMan-PCR performed in 4-months-old rats (n = 5 per group). (E) Sirius red stained cardiac sections of WT and CTGF-TG mice at age of 4 and 7 months as well as WT mice treated with isoproterenol as positive control (WT-mouse-ISO). Scale bars designate a length of 50 microm.
###end p 60
###begin p 61
(13.94 MB TIF)
###end p 61
###begin p 62
Click here for additional data file.
###end p 62
###begin p 63
###xml 117 123 <span type="species:ncbi:10090">murine</span>
Measurements of Ca2+-cycling and contractile function in single isolated cardiomyocytes at age of 3 months. Isolated murine cardiomyocytes were measured for (A) baseline cellular length, (B) FS, (C) contraction and (D) relaxation rate. The Ca2+-cycling was assessed by recording of such parameters like (E) cytosolic Ca2+ content in diastole, (F) amplitude of the Ca2+ wave, (G) velocity of the Ca2+ influx and (H) efflux from the cytosol. CTGF-TG cardiomyocytes n = 43, WT cardiomyocytes n = 38.
###end p 63
###begin p 64
(0.58 MB TIF)
###end p 64
###begin p 65
Click here for additional data file.
###end p 65
###begin p 66
###xml 388 392 <span type="species:ncbi:10090">mice</span>
Characterization of cardiac function at 3 months of age in ischemia/reperfusion model. The left ventricular pressures were assessed during 5 minutes of each phase (baseline, ischemia and reperfusion). We monitored (A) intracardiac pressure in systole (ICPsys), (B) intracardiac pressure in diastole (ICPdia), (C) contraction rate (ICPsys/sec), and (D) relaxation rate (ICPdia/sec), n = 7 mice per group.
###end p 66
###begin p 67
(0.60 MB TIF)
###end p 67
###begin p 68
Click here for additional data file.
###end p 68
###begin p 69
We would like to thank Friedrich C. Luft and Carmen Birchmeier for critically reading the manuscript. We gratefully acknowledge the help of Fatimunnisa Qadri and the excellent technical assistance of Tanja Schalow, Ariane Giese, Sabine Gruger, Astrid Schiche, Jutta Meisel and Martin Taube.
###end p 69
###begin title 70
References
###end title 70
###begin article-title 71
Incidence and epidemiology of heart failure.
###end article-title 71
###begin article-title 72
Long-term trends in the incidence of and survival with heart failure.
###end article-title 72
###begin article-title 73
Genomic circuits and the integrative biology of cardiac diseases.
###end article-title 73
###begin article-title 74
A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene.
###end article-title 74
###begin article-title 75
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling.
###end article-title 75
###begin article-title 76
Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia.
###end article-title 76
###begin article-title 77
Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?
###end article-title 77
###begin article-title 78
Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts.
###end article-title 78
###begin article-title 79
CCN proteins: multifunctional signalling regulators.
###end article-title 79
###begin article-title 80
The modular architecture of a new family of growth regulators related to connective tissue growth factor.
###end article-title 80
###begin article-title 81
###xml 144 148 <span type="species:ncbi:10090">mice</span>
Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice.
###end article-title 81
###begin article-title 82
Systemic and cell type-specific gene expression patterns in scleroderma skin.
###end article-title 82
###begin article-title 83
Pro: Inflammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary fibrosis.
###end article-title 83
###begin article-title 84
Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enterovirus myocarditis.
###end article-title 84
###begin article-title 85
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice.
###end article-title 85
###begin article-title 86
###xml 127 131 <span type="species:ncbi:10116">rats</span>
Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats.
###end article-title 86
###begin article-title 87
Gene expression changes associated with fibronectin-induced cardiac myocyte hypertrophy.
###end article-title 87
###begin article-title 88
Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: implication for cardiac fibrosis and hypertrophy.
###end article-title 88
###begin article-title 89
Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis.
###end article-title 89
###begin article-title 90
Differential regulation of angiotensin II-induced expression of connective tissue growth factor by protein kinase C isoforms in the myocardium.
###end article-title 90
###begin article-title 91
Connective tissue growth factor induces cardiac hypertrophy through Akt signaling.
###end article-title 91
###begin article-title 92
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure.
###end article-title 92
###begin article-title 93
###xml 139 144 <span type="species:ncbi:9606">human</span>
Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium.
###end article-title 93
###begin article-title 94
###xml 91 95 <span type="species:ncbi:9823">pigs</span>
Induction of myocardial connective tissue growth factor in pacing-induced heart failure in pigs.
###end article-title 94
###begin article-title 95
###xml 67 70 <span type="species:ncbi:10116">rat</span>
Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis.
###end article-title 95
###begin article-title 96
Adenoviral gene transfer of connective tissue growth factor in the lung induces transient fibrosis.
###end article-title 96
###begin article-title 97
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness.
###end article-title 97
###begin article-title 98
Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.
###end article-title 98
###begin article-title 99
Cardiac excitation-contraction coupling.
###end article-title 99
###begin article-title 100
###xml 57 62 <span type="species:ncbi:9606">human</span>
Cellular basis of abnormal calcium transients of failing human ventricular myocytes.
###end article-title 100
###begin article-title 101
Connective tissue growth factor and cardiac fibrosis after myocardial infarction.
###end article-title 101
###begin article-title 102
Brain renin-angiotensin system - focus on transgenic animal models.
###end article-title 102
###begin p 103
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 103
###begin p 104
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by The Berlin Institute for Heart Research (BIHR), the Competence Network of Heart Failure funded by the Federal Ministry of Education and Research (BMBF), FKZ 01GI0205 as well as PhD fellowship for A.N.P from Max-Delbruck-Center for Molecular Medicine Berlin-Buch. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 104

